Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Author(s) -
Stuart J. Connolly,
Mark Crowther,
John W. Eikelboom,
C. Michael Gibson,
John T. Curnutte,
John H. Lawrence,
Patrick Yue,
Michele Bronson,
Genmin Lu,
Pamela B. Conley,
Peter Verhamme,
Jeannot Schmidt,
Saskia Middeldorp,
Alexander T. Cohen,
Jan BeyerWestendorf,
Pierre Albaladejo,
José LópezSendón,
Andrew M. Demchuk,
Daniel J. Pallin,
Mauricio Concha,
Shelly Goodman,
Janet M. Leeds,
Sonia Souza,
Deborah Siegal,
Elena Zotova,
Brandi Meeks,
Sadia Ahmad,
Juliet Nakamya,
Truman J. Milling
Publication year - 2019
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1814051
Subject(s) - medicine , liter , bolus (digestion) , rivaroxaban , hemostasis , anesthesia , surgery , gastroenterology , warfarin , atrial fibrillation
Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom